Mostrar el registro sencillo del ítem

dc.contributor.authorEscalera Pérez, Raquel 
dc.contributor.authorMedina-Achirica, C.
dc.contributor.authorGarcía-Molina, F.J.
dc.contributor.authorDel Rio-Ignacio, J.J.
dc.contributor.authorLagares Franco, Carolina María 
dc.contributor.authorEstella García, Ángel 
dc.contributor.authorMateo Vallejo, Francisco de Asís 
dc.contributor.otherEstadística e Investigación Operativaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2026-11-04T11:33:09Z
dc.date.available2026-11-04T11:33:09Z
dc.date.issued2026
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/10498/40549
dc.description.abstractGastric cancer (GC) remains an oncological challenge, with lymph node involvement being a major prognostic factor. Sentinel lymph node (SLN) mapping may improve staging and reduce morbidity. This study evaluated a dual-tracer technique (superparamagnetic iron oxide: SPIO and methylene blue) for ex vivo detection; assessed one-step nucleic acid amplification (OSNA) versus conventional histology; and applied OSNA-pooling analysis in non-SLN. Prospective study of patients undergoing curative gastrectomy with lymphadenectomy (2017–2022). SLNs were identified in fresh specimens by Sentimag® and/or macroscopic staining. Each lymph node was bisected, with one half analyzed by hematoxylin–eosin (H&E) and the other by OSNA. Non-SLN were assessed using pooled OSNA to enhance diagnostic performance. Diagnostic performance metrics and agreement (Cohen’s κ) were calculated. Survival was estimated by Kaplan–Meier. Thirty-eight patients were included (mean age 64.3 years; 58% male); 71.1% received neoadjuvant therapy. SLN detection rate was 84.2% (32/38), with 80 SLNs identified. The dual-tracer approach demonstrated high sensitivity (93.1%) and moderate specificity (44.4%), resulting in an accuracy of 81.6%. Tracer concordance was moderate (κ = 0.42; p < 0.007). OSNA showed good agreement with H&E (sensitivity 80%, specificity 87%), and better performance for micrometastases. The pooling analysis evaluated 1155 non-SLN simultaneously; this novel strategy showed good concordance with conventional histology. After a median follow-up of 53 months, OSNA and H&E status were associated with overall survival in exploratory analyses; however, these findings should be interpreted with caution given the limited sample size and ex vivo proof-of-concept design. Combining SPIO and methylene blue is technically feasible for ex vivo SLN mapping. OSNA complements histology, and its pooled use represents an innovative methodological approach. These results are preliminary and hypothesis-generating; larger prospective in vivo studies are required before clinical applicability can be evaluated. Dual-tracer sentinel node mapping in gastric cancer proved feasible and accurate. OSNA complemented histology, pooled analysis improved detection efficiency, and neoadjuvant therapy did not affect diagnostic performance.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherNature Researches_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceScientific reports, Vol. 16, Núm. 1, 2026es_ES
dc.subjectIrones_ES
dc.subjectMethylene Bluees_ES
dc.subjectNucleic Acid Amplification Techniqueses_ES
dc.subjectSentinel Lymph Node Biopsyes_ES
dc.subjectStomach Neoplasmses_ES
dc.titleSentinel lymph node detection in gastric cancer using a dual tracer (Superparamagnetic iron oxide and methylene blue): a prospective study with histological and OSNA validationes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1038/S41598-026-43345-7
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional